Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback